Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
HAE Stock Forecast 2026-2027
$61.62
Current Price
$2.88B
Market Cap
Buy 7
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to HAE Price Targets
+75.3%
To High Target of $108.00
+41.2%
To Median Target of $87.00
+3.9%
To Low Target of $64.00
HAE Price Momentum
+7.5%
1 Week Change
+4.6%
1 Month Change
+7.8%
1 Year Change
-23.1%
Year-to-Date Change
-29.4%
From 52W High of $87.32
+30.2%
From 52W Low of $47.32
📊 TOP ANALYST CALLS
Did HAE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Haemonetics is one of their latest high-conviction picks.
Latest HAE Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, HAE has a bullish consensus with a median price target of $87.00 (ranging from $64.00 to $108.00). The overall analyst rating is Buy (7.8/10). Currently trading at $61.62, the median forecast implies a 41.2% upside. This outlook is supported by 7 Buy, 4 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Mike Matson at Needham, projecting a 75.3% upside. Conversely, the most conservative target is provided by Joanne Wuensch at Citigroup, suggesting a 3.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HAE Analyst Ratings
7
Buy
4
Hold
0
Sell
HAE Price Target Range
Low
$64.00
Average
$87.00
High
$108.00
Current: $61.62
Latest HAE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HAE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 13, 2026 | Mizuho | Anthony Petrone | Outperform | Maintains | $70.00 |
| Mar 11, 2026 | Citigroup | Joanne Wuensch | Neutral | Maintains | $70.00 |
| Feb 6, 2026 | Barrington Research | Michael Petusky | Outperform | Maintains | $94.00 |
| Feb 6, 2026 | BTIG | Marie Thibault | Buy | Reiterates | $88.00 |
| Feb 6, 2026 | Citigroup | Joanne Wuensch | Neutral | Maintains | $75.00 |
| Feb 6, 2026 | Mizuho | Anthony Petrone | Outperform | Maintains | $80.00 |
| Feb 2, 2026 | Barrington Research | Michael Petusky | Outperform | Maintains | $93.00 |
| Jan 12, 2026 | Barrington Research | Michael Petusky | Outperform | Maintains | $93.00 |
| Jan 9, 2026 | BTIG | Marie Thibault | Buy | Reiterates | $88.00 |
| Dec 17, 2025 | Mizuho | Anthony Petrone | Outperform | Maintains | $90.00 |
| Dec 15, 2025 | Needham | Mike Matson | Hold | Downgrade | $N/A |
| Dec 15, 2025 | Baird | David Rescott | Outperform | Maintains | $99.00 |
| Dec 12, 2025 | JP Morgan | Rohin Patel | Neutral | Maintains | $74.00 |
| Dec 11, 2025 | Citigroup | Joanne Wuensch | Neutral | Downgrade | $88.00 |
| Nov 21, 2025 | BTIG | Marie Thibault | Buy | Reiterates | $88.00 |
| Nov 7, 2025 | Barrington Research | Michael Petusky | Outperform | Maintains | $90.00 |
| Nov 7, 2025 | Needham | Mike Matson | Buy | Maintains | $78.00 |
| Nov 6, 2025 | BTIG | Marie Thibault | Buy | Maintains | $88.00 |
| Oct 21, 2025 | Barrington Research | Michael Petusky | Outperform | Maintains | $86.00 |
| Oct 7, 2025 | Citigroup | Joanne Wuensch | Buy | Maintains | $64.00 |
Haemonetics Corporation (HAE) Competitors
The following stocks are similar to Haemonetics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Haemonetics Corporation (HAE) Financial Data
Haemonetics Corporation has a market capitalization of $2.88B with a P/E ratio of 16.6x. The company generates $1.32B in trailing twelve-month revenue with a 13.3% profit margin.
Revenue growth is -2.7% quarter-over-quarter, while maintaining an operating margin of +21.0% and return on equity of +19.3%.
Valuation Metrics
Market Cap
$2.88B
Enterprise Value
$3.73B
P/E Ratio
16.6x
PEG Ratio
0.6x
Price/Sales
2.2x
Growth & Margins
Revenue Growth (YoY)
-2.7%
Gross Margin
+59.7%
Operating Margin
+21.0%
Net Margin
+13.3%
EPS Growth
+19.3%
Financial Health
Cash/Price Ratio
+12.7%
Current Ratio
1.7x
Debt/Equity
134.4x
ROE
+19.3%
ROA
+6.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Haemonetics Corporation (HAE) Business Model
About Haemonetics Corporation
What They Do
Provides innovative blood management solutions globally.
Business Model
Haemonetics generates revenue by offering a comprehensive portfolio of devices and services that enhance blood management for hospitals, blood centers, and plasma collection facilities. Its products include blood collection and processing systems, plasma collection devices, and software solutions, all designed to improve the efficiency and safety of blood supply operations.
Additional Information
Headquartered in Boston, Massachusetts, Haemonetics is dedicated to innovation in healthcare and plays a critical role in supporting the delivery of essential medical treatments and therapies worldwide.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
3,657
CEO
Mr. Christopher A. Simon
Country
United States
IPO Year
1991
Website
www.haemonetics.comHaemonetics Corporation (HAE) Latest News & Analysis
Latest News
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2026 Results: May 7, 2026
17 days ago
Quick Summary
Haemonetics Corporation (NYSE: HAE) will release Q4 fiscal 2026 results on May 7, 2026, at 6:00 am ET, followed by a conference call at 8:00 am ET.
Why It Matters
Haemonetics' upcoming financial results and conference call may impact stock performance, providing insights into company performance and future outlook crucial for investment decisions.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Haemonetics Corporation's VASCADE MVP XL system received FDA approval for use with larger sheaths (10-14F ID, up to 17F OD), expanding its application in pulsed field ablation and left atrial appendage closure.
Why It Matters
FDA approval for expanded use of VASCADE MVP XL enhances Haemonetics' product offerings in atrial fibrillation treatments, potentially boosting revenue and market competitiveness.
Source: PRNewsWire
Market Sentiment:
Neutral
What Investors Should Know About a $24 Million Exit From a Medical Device Stock Down 9% This Past Year
29 days ago
Quick Summary
Invenomic sold 498,317 shares of Haemonetics Corporation in Q4, resulting in a $24.29 million decrease in the fund's position value.
Why It Matters
Invenomic's sale of Haemonetics shares signals a significant reduction in their investment, potentially impacting Haemonetics' stock price and market sentiment.
Source: The Motley Fool
Market Sentiment:
Negative
Quick Summary
Zacks Premium research service offers Zacks Style Scores, aiding investors in identifying strong stocks across value, growth, and momentum categories.
Why It Matters
Zacks Style Scores can enhance stock selection by identifying strong investment opportunities across various strategies, potentially improving portfolio performance for investors.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Zacks Premium offers Style Scores to help investors of all types—value, growth, or momentum—identify strong stocks more easily.
Why It Matters
The mention of Zacks Style Scores highlights a tool that can enhance stock selection, potentially leading to better investment decisions and improved portfolio performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
HAE's NexSys PCS adoption and hospital recovery indicate potential growth, but a leveraged balance sheet and strong competition pose challenges for the stock's outlook.
Why It Matters
HAE's NexSys PCS adoption indicates potential revenue growth, but its leveraged balance sheet and competition may hinder stock performance and risk assessments.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About HAE Stock
What is Haemonetics Corporation's (HAE) stock forecast for 2026?
Based on our analysis of 15 Wall Street analysts, Haemonetics Corporation (HAE) has a median price target of $87.00. The highest price target is $108.00 and the lowest is $64.00.
Is HAE stock a good investment in 2026?
According to current analyst ratings, HAE has 7 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $61.62. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HAE stock?
Wall Street analysts predict HAE stock could reach $87.00 in the next 12 months. This represents a 41.2% increase from the current price of $61.62. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Haemonetics Corporation's business model?
Haemonetics generates revenue by offering a comprehensive portfolio of devices and services that enhance blood management for hospitals, blood centers, and plasma collection facilities. Its products include blood collection and processing systems, plasma collection devices, and software solutions, all designed to improve the efficiency and safety of blood supply operations.
What is the highest forecasted price for HAE Haemonetics Corporation?
The highest price target for HAE is $108.00 from Mike Matson at Needham, which represents a 75.3% increase from the current price of $61.62.
What is the lowest forecasted price for HAE Haemonetics Corporation?
The lowest price target for HAE is $64.00 from Joanne Wuensch at Citigroup, which represents a 3.9% increase from the current price of $61.62.
What is the overall HAE consensus from analysts for Haemonetics Corporation?
The overall analyst consensus for HAE is bullish. Out of 15 Wall Street analysts, 7 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $87.00.
How accurate are HAE stock price projections?
Stock price projections, including those for Haemonetics Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 19, 2026 8:44 AM UTC